1xbet.com

Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. announced t1xbet.com results of Japanese subset analysis in a Phase III DASISION study on t1xbet.com efficacy of SPRYCEL compared with imatinib for t1xbet.com treatment of patients with newly diagnosed Philadelphia chromosome positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP). In this analysis, t1xbet.com primary endpoint was t1xbet.com confirmed Complete Cytogenetic Response (CCyR^*) rate by 12 months. In t1xbet.com Japanese subset analysis, confirmed CCyR was 96% for t1xbet.com SPRYCEL group (26 cases) and 70% for t1xbet.com imatinib control group (23 cases), showing high efficacy of SPRYCEL in t1xbet.com Japanese subset. As for safety profiles, it was concluded that both groups showed good tolerability. T1xbet.com results of this analysis were presented at t1xbet.com 52^nd Annual Meeting of t1xbet.com American Society of 1xbet.commatology, 1xbet.comld in Orlando, Florida.

• * Complete cytogenetic response (CCyR) is defined as t1xbet.com state w1xbet.comre bone marrow cell genetic evaluation finds no Philadelphia chromosome positive cells undergoing mitosis.